At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
mifepristonedrug
Likely dose
mifepristone 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome
In Brief
A Phase 3 clinical trial evaluating mifepristone for Cushing's Syndrome. Completed, enrolled 30 participants across 15 sites.
Detailed Summary
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome. Total treatment duration may be up to 12 months or longer at the discretion of the Investigator.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCushing's Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionSep 2012
TodayJul 2026
First PostedJul 10, 2009
Enrollment StartJul 1, 2009
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 17.0 years ago
Interventions
mifepristonedrug
Mifepristone 300 mg to 1200 mg once daily